NH TherAguix raises 13 mln euros
NH TherAguix said April 11 that it closed a 13 million euros ($14.67 million) Series A round led by Bpifrance. Also participating were Supernova Invest, a previous investor, and Omnes and Arbevel. NH TherAguix is developing drug candidate AGuIX for the treatment of solid cancers.
11 April 2019•4 mins read
